Interleukin-35 (IL-35) and receptor (SJ-06-0016, SJ-08-0039)

Technology Name
(St. Jude Reference #)
Interleukin-35 (IL-35) and receptor (SJ-06-0016, SJ-08-0039)

IL-35 is an inhibitory cytokine discovered to be specifically produced by regulatory T cells (Treg cells) and integral to their suppressive activity. Ectopic expression of IL-35 confers regulatory activity on naïve T cells, while recombinant IL-35 suppresses T cell proliferation. Methods for modulating the immune system through IL35 inhibition based on this discovery are claimed. IL35 can be inhibited through use of an antibody or small molecule inhibitor. These methods inhibit Treg cell activity and can be used, for example, to overcome a suppressed immune response to a cancer vaccine.

The receptor for the IL-35 cytokine closely associated with Tregs can be used to develop methods to block or augment IL35R signaling to block or boost, respectively, IL-35 activity. This could be used to treat autoimmune and inflammatory diseases. Methods that block/inhibit IL35R signaling could be used to treat any condition in which the IL-35-mediated activity of Tregs is shown to blocking/limiting disease resolution such as cancer and chronic inflammatory disease.

Keywords  Cancer, T cell, virus, vaccine, IL-35, Interleukin
Granted Patents or Published Applications Australian Patent Issued 2007298571, Patents applications pending in the U.S., Europe and Canada
Related Scientific References  
Licensing Opportunities We are currently seeking a partner to commercialize all aspects of this technology.


Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.


Last update: June 2014